Erica Mayer

29PUBLICATIONS
215CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Health informatics and information systemsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 30, 2026
Giredestrant plus Everolimus in Advanced Breast Cancer.

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Jun 02, 2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

François-Clément Bidard, Erica L Mayer, Yeon Hee Park

|Feb 06, 2025
Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.

Erica L Mayer, Mary Lou Smith, Annie Guérin

|Oct 09, 2024
Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.

Alexandra Thomas, Erica L Mayer, Angela DeMichele

|Sep 03, 2024
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer.

Antonio Giordano, Priya U Kumthekar, Qingchun Jin

Pageof 5

Frequent Collaborators

8 joint publications

Angela M DeMichele

7 joint publications

Sara Tolaney

7 joint publications

Antonio C Wolff

6 joint publications

Eric P Winer